• About us
    • Who we are
    • Our strategy
    • How we are funded
    • Our people
    • Reports and statements
    • Governance and structure
    • Our impact
  • Working with us
    • Support for MRC researchers
    • Helping charities
    • Our partners
    • Advise & Connect: Covid-19
    • Licensing opportunities
  • Funding
    • LifeArc Ventures
    • Rare disease research funding
    • Development Gap Fund
  • Capabilities
    • Drug discovery
    • Antibody engineering
    • IP management and technology transfer
    • Diagnostics development
  • Careers
    • Jobs
    • Industrial Placements
    • Fellowships
  • News
    • Latest news
    • Case studies
    • Reports and publications
    • Newsletter
    • Covid-19 Information
    • Media contacts
  • Contact us

A selection of our portfolio

About
Our ventures team
Portfolio companies
News
Contact

Our companies

AviadoBio
AviadoBio
AviadoBio

Developing transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders

Find out more
Avvinity Therapeutics
Avvinity Therapeutics
Avvinity Therapeutics

Developing novel immunotherapeutics known as Alphamers®, which redirect a patient’s existing antibodies to kill cancer cells and boost immune surveillance

Find out more
Caldan Therapeutics
Caldan Therapeutics
Caldan Therapeutics

Developing activators of free fatty acid receptors to treat metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH)

Find out more
Closed Loop Medicines
Closed Loop Medicines
Closed Loop Medicines

Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians

Find out more
Cumulus Neuroscience 
Cumulus Neuroscience 
Cumulus Neuroscience 

Their next-generation integrated physiological and digital biomarker platform can monitor diseases of the central nervous system at home – providing feedback on disease progression and response to treatment

Find out more
DJS Antibodies
DJS Antibodies
DJS Antibodies

Developing novel antibodies to G-protein coupled receptor (GPCR) targets to treat inflammatory diseases (chronic kidney disease and myeloid driven inflammatory disease) using their proprietary HEPTAD discovery technology

Find out more
Ducentis BioTherapeutics
Ducentis BioTherapeutics
Ducentis BioTherapeutics

Developing novel therapies for inflammation and autoimmune disease

Find out more
Eliem Therapeutics, Inc (NASDAQ: ELYM)
Eliem Therapeutics, Inc (NASDAQ: ELYM)
Eliem Therapeutics, Inc (NASDAQ: ELYM)

Developing ETX-810 to treat chronic pain, and ETX-155, to treat major depressive disorder, perimenopausal depression and focal onset seizures. LifeArc invested alongside RA Capital, Intermediate Capital Group, Access Biotechnology, Samlyn Capital and Acorn Bioventures in a $60 million Series B financing in May 2021.

Find out more
Ikarovec
Ikarovec
Ikarovec

Developing novel, differentiated gene therapies for eye conditions, including diabetic macular oedema, age-related macular degeneration (AMD) and intra-ocular hypertension

Find out more
Pheno Therapeutics 
Pheno Therapeutics 
Pheno Therapeutics 

Discovering and developing small molecules to promote remyelination to treat multiple sclerosis

Find out more
Quick links
  • Newsletter
  • Media contacts
  • Privacy policy
  • Cookie policy
  • Modern slavery statement
  • Sitemap
Follow us
Get in touch
Lynton House
7-12 Tavistock Square
London WC1H 9LT UK

+44 (0)20 7391 2700
LifeArc is a charity registered with the Charity Commission for England and Wales no. 1015243 and a charity registered in Scotland with the Office of the Scottish Charity Regulator no. SC037861. LifeArc is a company limited by guarantee no. 2698321 incorporated in England and Wales. | © LifeArc 2022
Web design by TWK